Monopar Therapeutics

Company snapshot

Monopar Therapeutics is a clinical-stage biopharmaceutical company developing ALXN1840, a late-stage therapy for Wilson disease, and a radiopharmaceutical pipeline targeting advanced cancers, including MNPR-101-Zr and MNPR-101-Lu in Phase 1 clinical trials and MNPR-101-Ac225 in late preclinical development.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Monopar Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Monopar Therapeutics.

1. Jun 8, 2026 Clinical update

   Clonidine HCl Mucoadhesive Buccal Tablet — Phase 3

2. May 23, 2026 Clinical update

   Camsirubicin — Phase 1

3. May 23, 2026 Clinical update

   MNPR-101-DFO*-89Zr — Phase 1

4. May 23, 2026 Clinical update

   MNPR-101-PCTA-177Lu — Phase 1

5. Aug 17, 2021 Patent grant

   Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy

View all clinical trial activity →

• What is Monopar Therapeutics?

  Monopar Therapeutics is a pharma organization headquartered in Wilmette, USA. It trades on NYSE under ticker MNPR. Primary therapeutic focus areas include Solid Tumor, Adult, Advanced Soft-tissue Sarcoma, Chemoradiotherapy-Induced Severe Oral Mucositis. NovaPharmaNews links 4 cli

• Is Monopar Therapeutics publicly traded?

  Yes. Monopar Therapeutics is listed with ticker MNPR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Monopar Therapeutics develop or market?

  We link 3 drug profile(s) where Monopar Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/monopar-therapeutics#company-drugs.

• What are the latest developments for Monopar Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Monopar Therapeutics focus on?

  Monopar Therapeutics focuses on Solid Tumor, Adult, Advanced Soft-tissue Sarcoma, Chemoradiotherapy-Induced Severe Oral Mucositis based on our analysis of their pipeline programs and drug development activities.